Fundz

NurExone Biologic

Haifa, Israel · Biotechnology

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

Key facts

Headquarters
Haifa, Israel
Employees
25
Industries
Biotechnology
Status
Private
Website
nurexone.com
LinkedIn
Company page

Recent activity at NurExone Biologic

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

NurExone Biologic funding history

DateRoundAmount
Aug 2026Post-IPO Equity$450K
Jun 2026Venture$442K
Mar 2026Venture$280K
Aug 2025Venture$148K
Apr 2025Venture$1.6M

Leadership

  • Limor Chen, Head of Scientific Collaborations & External Partnerships
  • Oded Orgil, Director
  • Yoram Drucker, Director
  • Gadi Riesenfeld, Director
  • Eran Ovadya, Executive Officer
  • Lior Shaltiel, Director

Verified email and direct lines for NurExone Biologic’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

NurExone Biologic in the news

Companies similar to NurExone Biologic

About NurExone Biologic: questions and answers

What does NurExone Biologic do?

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

Where is NurExone Biologic headquartered?

NurExone Biologic is headquartered in Haifa, Israel.

How many employees does NurExone Biologic have?

NurExone Biologic has about 25 employees.

Has NurExone Biologic raised funding?

Yes. Fundz has recorded 5 funding events for NurExone Biologic. The most recent, Post-IPO Equity of $450K, was in Aug 2026.

What is the latest news on NurExone Biologic?

On Aug 22, 2026, NurExone Biologic Enters 5-Year Manufacturing Partnership with Made Scientific for Bone-Marrow-Derived Exosomes.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches NurExone Biologic across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.